EMEA-002826-PIP01-20

Key facts

Active substance
remdesivir
Therapeutic area
Infectious diseases
Decision number
P/0201/2020
PIP number
EMEA-002826-PIP01-20
Pharmaceutical form(s)
  • Powder for concentrate for solution for infusion
  • Concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of Coronavirus disease 2019
Route(s) of administration
Intravenous use
Contact for public enquiries
Gilead Sciences International Ltd

E-mail: regulatory.pip@gilead.com
Tel. +44 (0)1223 897300

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating
Average
1 rating